CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
14.46
3.08%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 14.92
Open 14.69
1-Year Change -26.48%
Day's Range 14.15 - 14.69
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 14.46 -0.01 -0.07% 14.47 15.06 14.04
Dec 19, 2024 14.92 -0.14 -0.93% 15.06 15.27 14.45
Dec 18, 2024 15.28 -0.42 -2.68% 15.70 16.60 15.10
Dec 17, 2024 15.87 -0.57 -3.47% 16.44 16.48 15.00
Dec 16, 2024 16.56 1.34 8.80% 15.22 17.24 15.22
Dec 13, 2024 15.46 0.92 6.33% 14.54 15.68 14.45
Dec 12, 2024 14.95 -0.55 -3.55% 15.50 16.54 14.75
Dec 11, 2024 15.44 1.28 9.04% 14.16 16.88 14.16
Dec 10, 2024 23.05 0.46 2.04% 22.59 23.26 22.07
Dec 9, 2024 22.79 -1.58 -6.48% 24.37 25.75 22.71
Dec 6, 2024 24.81 1.36 5.80% 23.45 24.87 23.45
Dec 5, 2024 23.52 -0.43 -1.80% 23.95 25.07 23.25
Dec 4, 2024 23.98 2.02 9.20% 21.96 24.50 21.95
Dec 3, 2024 21.93 -2.72 -11.03% 24.65 24.76 21.52
Dec 2, 2024 24.32 0.92 3.93% 23.40 24.54 22.03
Nov 29, 2024 24.79 0.04 0.16% 24.75 25.22 24.29
Nov 27, 2024 25.07 -0.02 -0.08% 25.09 26.25 24.67
Nov 26, 2024 25.20 1.45 6.11% 23.75 25.24 22.69
Nov 25, 2024 23.95 1.43 6.35% 22.52 25.05 22.27
Nov 22, 2024 22.20 1.17 5.56% 21.03 22.28 20.35

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AnaptysBio Company profile

About AnaptysBio Inc

AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AnaptysBio Inc revenues decreased 16% to $63.2M. Net loss increased from $19.9M to $57.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 22% to $92.6M (expense), Interest income decrease of 89% to $431K (income).

Industry: Bio Therapeutic Drugs

10770 Wateridge Circle, Suite 210
SAN DIEGO
CALIFORNIA 92121
US

People also watch

XRP/USD

2.22 Price
-0.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01107

BTC/USD

95,385.90 Price
-1.350% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

TSLA

422.33 Price
-3.790% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 0.19

ETH/USD

3,291.68 Price
-0.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading